List of Excipients in Branded Drug ERGOTAMINE

Generic Drugs Containing ERGOTAMINE

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceutical Corp	ergotamine tartrate and caffeine	0143-2120	CELLULOSE, MICROCRYSTALLINE
West-Ward Pharmaceutical Corp	ergotamine tartrate and caffeine	0143-2120	FD&C BLUE NO. 2
West-Ward Pharmaceutical Corp	ergotamine tartrate and caffeine	0143-2120	FD&C YELLOW NO. 6
West-Ward Pharmaceutical Corp	ergotamine tartrate and caffeine	0143-2120	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in ERGOTAMINE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	FD&C BLUE NO. 2
1	FD&C YELLOW NO. 6
1	FERROSOFERRIC OXIDE

# Ergotamine Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Ergotamine is an old, highly potent antimigraine drug with limited modern commercial reach. The strongest opportunities are in low-dose sublingual, buccal, orally disintegrating, and combination products that improve dose uniformity, taste, stability, and patient convenience. The main commercial barriers are narrow therapeutic margin, vasoconstrictive safety risks, limited market demand relative to triptans and CGRP therapies, and the regulatory burden of proving bioequivalence for a low-dose product.

What is the commercial status of ergotamine?

Ergotamine is an ergot alkaloid used for acute migraine treatment. In the United States, historical products included ergotamine tartrate sublingual tablets and ergotamine-caffeine combinations. Product availability has been inconsistent, and several legacy products have been discontinued or have limited distribution. Current regulatory status should be assessed product by product through FDA labeling, the Orange Book, and current National Drug Code listings.[1][2]

Ergotamine is generally used in doses measured in milligrams or fractions of a milligram. Its pharmacology creates a difficult formulation profile:

• Low dose increases content-uniformity risk.
• Oral exposure is limited by extensive first-pass metabolism.
• The drug has potent vasoconstrictive activity.
• CYP3A4 inhibitors can materially increase exposure.
• Excessive dosing can produce serious peripheral or coronary vasospasm.
• Patient use is intermittent, which limits adherence-based commercial differentiation.

The principal excipient opportunity is therefore not simple cost reduction. It is the controlled design of a rapid, uniform, stable, and acceptable transmucosal dose.

What excipients are most suitable for ergotamine tablets?

For a low-dose ergotamine tartrate tablet, the preferred excipient system is likely to combine a highly functional diluent, a rapid disintegrant, a low-level binder, and a lubricant selected for minimal impact on wetting and dissolution.

Formulation function	Candidate excipients	Commercial rationale
Dilution and compressibility	Mannitol, microcrystalline cellulose, lactose, compressible sucrose	Supports low-dose blending and tablet robustness
Rapid disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports sublingual or orally disintegrating performance
Binding	Povidone, copovidone, low-viscosity hydroxypropyl cellulose	Improves granule and tablet strength
Taste management	Mannitol, sucralose, acesulfame potassium, flavor systems	Important for sublingual residence time
Lubrication	Magnesium stearate, sodium stearyl fumarate	Controls ejection and manufacturing robustness
Moisture control	Colloidal silicon dioxide, low-moisture excipient grades	Reduces flow and stability risks
Film or coating	Hypromellose, polyvinyl alcohol, methacrylate polymers	Enables identification, taste masking, or modified release

Mannitol is commercially attractive because it has good mouthfeel and is available in direct-compression and orally disintegrating grades. Microcrystalline cellulose can improve tablet strength but may produce a less desirable mouthfeel in a sublingual dosage form. Crospovidone is often preferable when rapid wicking and low swelling are needed. Croscarmellose sodium may provide strong disintegration but can create excessive swelling or a gritty oral experience at higher levels.

Lactose is technically viable, but its selection should be evaluated against patient population, supplier control, moisture behavior, and any target-market labeling requirements. Excipient compatibility must be tested with ergotamine tartrate rather than inferred from conventional migraine tablets.

What excipient strategy is best for a sublingual ergotamine product?

A sublingual tablet is the most logical reformulation platform because legacy ergotamine products used this route to reduce reliance on gastrointestinal absorption. The commercial target should be fast wetting, rapid tablet erosion, low residue, and reproducible exposure.

Recommended sublingual design

A practical starting platform would use:

1. Mannitol or a mannitol-cellulose blend as the principal diluent.
2. Crospovidone as the primary disintegrant.
3. A low level of povidone or copovidone if granulation is required.
4. Sodium stearyl fumarate or a carefully controlled magnesium stearate level.
5. A sweetener and flavor selected through sensory testing.
6. Moisture-protective packaging, preferably high-barrier blister packaging.

The formulation should avoid excessive hydrophobic lubricant, high polymer loading, and unnecessary coating. These components can slow wetting and create variable transmucosal contact.

Dose uniformity is a central development issue. At a 1 mg or 2 mg strength, ordinary geometric dilution may be insufficient for commercial-scale production. Options include ordered mixing, controlled granulation, spray layering onto a carrier, or preparation of a validated premix. The selected process must show uniformity across beginning, middle, and end-of-run samples.

The product should be evaluated for:

• Assay and content uniformity.
• Sublingual disintegration time.
• Wetting time and water uptake.
• Dissolution under physiologically relevant conditions.
• Residual drug after tablet erosion.
• Taste and mouthfeel.
• Stability under heat and humidity.
• Light sensitivity and packaging interaction.
• In vitro permeability, where relevant.
• Pharmacokinetic comparability against the reference product.

A faster-disintegrating tablet is not automatically superior. Excessively rapid release may increase swallowed drug, alter systemic exposure, and weaken the rationale for a sublingual route.

Could ergotamine be developed as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could create a more manufacturable and patient-friendly product than a conventional sublingual tablet, but it may not reproduce the same pharmacokinetic behavior.

An orally disintegrating product typically dissolves in the mouth and is then swallowed. Only part of the dose may bypass first-pass metabolism. A formulation that claims sublingual or buccal absorption would require stronger clinical and pharmacokinetic support than a standard oral product.

Potential ODT technologies include:

• Direct-compression mannitol systems.
• Lyophilized wafer systems.
• Spray-dried porous particles.
• Co-processed excipient platforms.
• Rapidly dispersible mini-tablets.

Direct compression is likely the most commercially practical. Lyophilized systems may offer rapid dispersion but can have higher manufacturing cost, fragile packaging, and more complex scale-up. Spray-dried systems can improve disintegration but require tight control of particle engineering and solvent removal.

Taste masking is difficult because ergot alkaloids can produce a bitter or unpleasant oral sensation. A polymer-coated microparticle or ion-exchange approach could improve palatability, but excessive encapsulation may delay release and reduce transmucosal availability.

What formulation patents could protect an ergotamine product?

Historic ergotamine compound patents are unlikely to provide meaningful current exclusivity because ergotamine was identified and used clinically many decades ago. Commercial protection would instead need to arise from a new formulation, manufacturing process, delivery device, or combination.

Potential patentable subject matter includes:

Patent area	Example claim concept	Commercial value
Sublingual composition	Ergotamine tartrate with defined diluent-disintegrant ratios	Protects a differentiated tablet
Content uniformity	Premix or ordered-blending process for submilligram dosing	Creates a manufacturing barrier
Taste masking	Coated ergotamine particles with rapid release	Supports patient acceptability
Buccal delivery	Mucoadhesive film with controlled ergotamine release	Differentiates route and dosage form
Moisture protection	Specific blister and desiccant configuration	Supports stability claims
Combination product	Ergotamine with caffeine or another approved component	May improve exposure or clinical utility
Device system	Metered nasal or buccal delivery apparatus	Protects product-device integration
Manufacturing process	Low-shear granulation or carrier-layering process	Can protect reproducibility

Patent strength will depend on claim breadth, enablement, unexpected pharmacokinetic results, and the availability of design-around routes. A broad claim covering “ergotamine and a disintegrant” would likely face validity and obviousness challenges. Stronger claims would specify narrow excipient ranges tied to measurable performance, such as rapid disintegration, reduced swallowed fraction, improved stability, or demonstrated bioequivalence.

What FDA pathway applies to an ergotamine reformulation?

The pathway depends on the reference product and the nature of the proposed change.

Abbreviated New Drug Application

A conventional generic tablet may be eligible for an ANDA under section 505(j) if FDA identifies a suitable reference listed drug and the proposed product matches the reference in active ingredient, dosage form, route, strength, and relevant performance characteristics.[3]

The principal risks are:

• An unavailable or discontinued reference product.
• Difficulty establishing a reliable reference for sublingual performance.
• Low-dose content-uniformity failures.
• Pharmacokinetic variability.
• Unclear equivalence between sublingual and orally disintegrating products.

505(b)(2) application

A 505(b)(2) application may be more appropriate for a new dosage form, new route, new formulation, or new combination that relies partly on FDA findings for an approved ergotamine product.[4] This pathway could support:

• A buccal film.
• A new orally disintegrating dosage form.
• A new ergotamine-caffeine ratio.
• A nasal formulation.
• A modified-release product, although modified release is commercially difficult for an acute migraine drug.

A 505(b)(2) product may obtain regulatory exclusivity, but the period depends on the specific approval and is separate from patent protection. FDA approval does not eliminate the need to evaluate listed patents and certification obligations.

Is ergotamine-caffeine a stronger commercial opportunity?

Ergotamine-caffeine combinations have historical precedent and may offer a more defensible formulation concept than ergotamine alone. Caffeine has been used in combination products to enhance ergotamine absorption and therapeutic effect. The combination also creates opportunities for differentiated strength ratios, rapid-release tablets, and dual-layer dosage forms.

The commercial limitations are substantial:

• Caffeine can affect tolerability and sleep.
• The combination does not remove ergotamine’s vasoconstrictive warnings.
• Modern migraine guidelines and prescribing patterns favor triptans and CGRP-targeted therapies for many patients.
• A new combination would require careful justification of dose ratio and clinical relevance.
• Patent claims must distinguish the product from expired combination disclosures.

A fixed combination may have greater commercial differentiation but a more demanding regulatory package than a straightforward generic.

What other delivery systems could create commercial value?

Buccal films

A buccal film could provide rapid dissolution, precise unit dosing, and improved portability. Film development must control drug loading, uniformity across the web, adhesion, folding endurance, and taste. Because ergotamine dose is low, a film platform is technically feasible. However, mucosal irritation and variable saliva exposure could affect performance.

Nasal delivery

A nasal spray could bypass first-pass metabolism and offer rapid onset. The commercial case is less favorable because ergotamine itself can cause vasoconstriction, while nasal excipients and repeated dosing may produce local tolerability concerns. A nasal product would require extensive device, spray-pattern, microbiological, and pharmacokinetic work.

Rectal delivery

Rectal ergotamine products have historical precedent in some markets, but the route has declining patient acceptance and limited differentiation. It may remain relevant where oral and sublingual products are unavailable, but it is unlikely to be the preferred global platform.

Lipid and nano-enabled systems

Self-emulsifying systems, lipid nanoparticles, and amorphous dispersions could improve oral exposure. The commercial benefit is uncertain because increasing systemic exposure may increase safety risk. These technologies are more defensible when they solve a demonstrated bioavailability problem without producing uncontrolled exposure.

What are the main manufacturing and IP barriers?

The most important manufacturing barriers are low-dose uniformity, raw-material variability, stability, and scale-up. Ergotamine tartrate should be controlled for assay, impurity profile, particle size, polymorphic or solid-state behavior, and moisture content.

A commercially credible product should use:

• Qualified suppliers with dual-source planning.
• A validated low-dose blending strategy.
• In-process controls for blend uniformity.
• High-barrier packaging.
• Stability-indicating analytical methods.
• Tight control of tablet weight and hardness.
• Defined limits for degradation products.
• A process capable of demonstrating reproducibility at commercial scale.

The IP estate for an ergotamine reformulation would likely be narrow unless supported by a genuinely differentiated delivery platform. The strongest protection would combine composition claims, process claims, packaging claims, and clinical or pharmacokinetic data. A single excipient-ratio patent would be vulnerable to substitution with another diluent or disintegrant.

How does ergotamine compare with modern migraine products?

Product class	Primary advantage	Main limitation versus ergotamine
Triptans	Established acute efficacy and broad availability	Vasoconstrictive restrictions remain for some patients
Gepants	No direct vasoconstrictive mechanism	Higher acquisition cost and newer market competition
Ditans	Non-vasoconstrictive option	Sedation and driving restrictions
CGRP antibodies	Preventive efficacy	Injectable administration and high cost
Ergotamine	Low-cost legacy active with rapid-route potential	Safety restrictions, tolerability, and limited current demand

Ergotamine’s commercial position is strongest in markets where price, product availability, or specific historical clinical use outweighs the advantages of newer agents. A reformulated product needs a clear benefit in onset, portability, tolerability, or access.

What is the most attractive commercial strategy?

The most practical strategy is a low-cost, high-quality sublingual or orally disintegrating ergotamine tartrate product using a mannitol-based, rapid-disintegration platform and moisture-protective packaging. A second-stage opportunity is a buccal film or ergotamine-caffeine combination supported by pharmacokinetic differentiation.

The preferred sequence is:

1. Establish the current reference-product and regulatory pathway.
2. Develop a low-dose premix and direct-compression platform.
3. Optimize disintegration without excessive swallowing.
4. Confirm taste and mucosal tolerability.
5. Generate comparative pharmacokinetic data.
6. File composition and manufacturing-process patents.
7. Extend protection through packaging, film, or device claims.
8. Target markets with persistent ergotamine demand and limited access to newer migraine agents.

Key Takeaways

• Ergotamine is an old active ingredient with limited value from conventional compound patents.
• The most credible opportunity is a rapid, uniform sublingual or orally disintegrating product.
• Mannitol, crospovidone, controlled lubrication, and high-barrier packaging are logical starting points.
• Low-dose content uniformity is the central manufacturing challenge.
• A buccal film could offer stronger product differentiation than a standard tablet.
• A 505(b)(2) pathway may be relevant for a new route, dosage form, or combination.
• Ergotamine-caffeine has historical precedent but does not eliminate vasoconstrictive safety constraints.
• Patent value will depend on measurable performance advantages, not generic excipient substitution.
• Commercial success depends on low cost, reliable supply, rapid administration, and market access rather than broad therapeutic expansion.

FAQs

Can mannitol be used in ergotamine sublingual tablets?

Yes. Mannitol is a strong candidate because it supports direct compression, rapid dissolution, and acceptable oral mouthfeel. The selected grade must be tested for flow, particle size, moisture, and compatibility with ergotamine tartrate.

Is an ergotamine oral film patentable?

Potentially. Patentability may arise from a defined film composition, drug-loading process, mucoadhesive system, taste-masking architecture, or demonstrated pharmacokinetic advantage. Generic claims to ergotamine in a film would face a higher validity risk.

Does caffeine improve ergotamine absorption?

Historically, caffeine has been included in ergotamine combination products and may improve absorption or clinical performance. Any new combination requires product-specific pharmacokinetic and regulatory justification.

Are biosimilar competitors relevant to ergotamine?

No. Ergotamine is a small-molecule drug, so the relevant competitive pathways are generic ANDAs, 505(b)(2) applications, and non-U.S. abridged or hybrid applications rather than biosimilar filings.

What packaging is preferable for ergotamine tablets?

High-barrier blister packaging is generally preferable to protect a low-dose product from moisture and handling variability. Packaging selection must be supported by stability data for the final formulation and market-specific storage conditions.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (2015). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/regulatory-information
4. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). https://www.fda.gov/regulatory-information
5. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/
6. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. https://www.ich.org/page/quality-guidelines
7. International Council for Harmonisation. (2005). ICH Q9: Quality risk management. https://www.ich.org/page/quality-guidelines
8. National Library of Medicine. (n.d.). DailyMed: Current medication labeling. https://dailymed.nlm.nih.gov/dailymed/